CLINICAL RESEARCH: HEART FAILURE
Incidence and Predictors of Hyperkalemia in Patients With Heart FailureAn Analysis of the CHARM Program
Akshay S. Desai, MD*,*,
Karl Swedberg, MD, PhD, FACC ,
John J.V. McMurray, MD, FACC ,
Christopher B. Granger, MD, FACC ,
Salim Yusuf, MD, Dphil, FACC||,
James B. Young, MD, FACC¶,
Mark E. Dunlap, MD, FACC#,
Scott D. Solomon, MD*,
James W. Hainer, MD**,
Bertil Olofsson, PhD,
Eric L. Michelson, MD, FACC**,
Marc A. Pfeffer, MD, PhD, FACC* CHARM Program Investigators
* Department of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts
Emergency and Cardiovascular Medicine, Sahlgrenska Academy, Göteborg University, Göteborg, Sweden
Department of Cardiology, Western Infirmary, Glasgow, Scotland
Department of Cardiology, Duke University Medical Center, Durham, North Carolina
|| Department of Medicine, HGM-McMaster Clinic, Hamilton, Ontario, Canada
¶ Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio
# Department of Cardiology, Case Western Reserve University and VA Medical Center, Cleveland, Ohio
** AstraZeneca LP, Wilmington, Delaware
AstraZeneca R&D, Mölndal, Sweden
Manuscript received June 19, 2007;
revised manuscript received July 26, 2007,
accepted July 31, 2007.
* Reprint requests and correspondence: Dr. Akshay S. Desai, PBB-A3, AB370, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115. (Email: adesai{at}partners.org).
Objectives: We explored the incidence and predictors of hyperkalemia in a broad population of heart failure patients.
Background: When used in optimal doses to treat patients with heart failure, renin-angiotensin-aldosterone system (RAAS) inhibitors improve clinical outcomes but can cause hyperkalemia.
Methods: Participants in the CHARM (Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity) (n = 7,599) Program were randomized to standard heart failure therapy plus candesartan or placebo, titrated as tolerated to a target of 32 mg once daily with recommended monitoring of serum potassium and creatinine. We assessed the incidence and predictors of hyperkalemia associated with dose reduction, study drug discontinuation, hospitalization, or death over the median 3.2 years of follow-up.
Results: Independent of treatment assignment, the risk of hyperkalemia increased with age  75 years, male gender, diabetes, creatinine 2.0 mg/dl, K+ 5.0 mmol/l, and background use of angiotensin-converting enzyme inhibitors or spironolactone. Candesartan increased the rate of aggregate hyperkalemia from 1.8% to 5.2% (difference 3.4%, p < 0.0001) and serious hyperkalemia (associated with death or hospitalization) from 1.1% to 1.8% (difference 0.7%, p < 0.001), with hyperkalemia associated with death reported in 2 (0.05%) candesartan patients and 1 (0.03%) placebo patient. The benefit of candesartan in reducing cardiovascular death or heart failure hospitalization (relative risk reduction 16%, p < 0.0001) was uniform in these subgroups, as was the incremental risk of hyperkalemia.
Conclusions: The risk of hyperkalemia is increased in symptomatic heart failure patients with advanced age, male gender, baseline hyperkalemia, renal failure, diabetes, or combined RAAS blockade. Although these groups derive incremental clinical benefit from candesartan, careful surveillance of serum potassium and creatinine is particularly important.
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | ARB = angiotensin receptor blocker | | CI = confidence interval | | CV = cardiovascular | | eGFR = glomerular filtration rate estimated by the Modification of Diet in Renal Disease method | | HF = heart failure | | LVEF = left ventricular ejection fraction | | OR = odds ratio | | RAAS = renin-angiotensin-aldosterone system |
|
This article has been cited by other articles:
|
|
|
|
 
A. M. Shah, S. H. Shin, M. Takeuchi, H. Skali, A. S. Desai, L. Kober, A. P. Maggioni, J. L. Rouleau, R. Y. Kelly, A. Hester, et al.
Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren
Eur J Heart Fail,
February 1, 2012;
14(2):
185 - 192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Antoniou, T. Gomes, M. M. Mamdani, Z. Yao, C. Hellings, A. X. Garg, M. A. Weir, and D. N. Juurlink
Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study
BMJ,
September 12, 2011;
343(sep12_1):
d5228 - d5228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. I. Chang and G. M. Chertow
Chronic Kidney Disease and Cardiovascular Therapeutics: Time to Close the Evidence Gaps
J. Am. Coll. Cardiol.,
September 6, 2011;
58(11):
1162 - 1164.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Pitt, R. Latini, A. P. Maggioni, S. D. Solomon, B. A. Smith, M. Wright, M. F. Prescott, and J. J. V. McMurray
Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study
Eur J Heart Fail,
July 1, 2011;
13(7):
755 - 764.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. W. Tobe, C. M. Clase, P. Gao, M. McQueen, A. Grosshennig, X. Wang, K. K. Teo, S. Yusuf, J. F. E. Mann, and on behalf of the ONTARGET and TRANSCEND Investigat
Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk: Results From the ONTARGET and TRANSCEND Studies
Circulation,
March 15, 2011;
123(10):
1098 - 1107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Weir, D. N. Juurlink, T. Gomes, M. Mamdani, D. G. Hackam, A. K. Jain, and A. X. Garg
Beta-Blockers, Trimethoprim-Sulfamethoxazole, and the Risk of Hyperkalemia Requiring Hospitalization in the Elderly: A Nested Case-Control Study
Clin. J. Am. Soc. Nephrol.,
September 1, 2010;
5(9):
1544 - 1551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Weir and M. Rolfe
Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors
Clin. J. Am. Soc. Nephrol.,
March 1, 2010;
5(3):
531 - 548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Poggio, H. O. Grancelli, and S. G. Miriuka
Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism
Postgrad. Med. J.,
March 1, 2010;
86(1013):
136 - 142.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J.V. McMurray, C. B. Granger, J. Ostergren, S. Yusuf, M. A. Pfeffer, and K. Swedberg
Dual Renin-Angiotensin system blockade in heart failure.
J. Am. Coll. Cardiol.,
July 14, 2009;
54(3):
278 - 278.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Preston, D. Afshartous, D. Garg, S. Medrano, A. B. Alonso, and R. Rodriguez
Mechanisms of Impaired Potassium Handling With Dual Renin-Angiotensin-Aldosterone Blockade in Chronic Kidney Disease
Hypertension,
May 1, 2009;
53(5):
754 - 760.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Ezekowitz and F. A. McAlister
Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials
Eur. Heart J.,
February 2, 2009;
30(4):
469 - 477.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Dunn, B. Bleske, M. Dorsch, T. Macaulay, B. Van Tassell, and O. Vardeny
Nutrition and Heart Failure: Impact of Drug Therapies and Management Strategies
Nutr Clin Pract,
February 1, 2009;
24(1):
60 - 75.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. McMurray, M. Petrie, K. Swedberg, M. Komajda, S. Anker, and R. Gardner
CHAPTER 23 Heart Failure
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Desai
Hyperkalemia Associated With Inhibitors of the Renin-Angiotensin-Aldosterone System: Balancing Risk and Benefit
Circulation,
October 14, 2008;
118(16):
1609 - 1611.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Weinrauch, J. Lin, and S. D. Solomon
Mapping Directions for the Cardiorenal Conundrum: Where You End Up Depends Upon Where You Started, So Where Do We Go From Here?
J. Am. Coll. Cardiol.,
April 1, 2008;
51(13):
1275 - 1276.
[Full Text]
[PDF]
|
|
|
|
